Peptide side effects
Every medication that does something can do something unwanted. These articles catalogue peptide side effects and those reported for GLP-1 medications — nausea, injection-site reactions, and the rarer things worth knowing about — plus what researchers report about how long effects last and what tends to help.
Honest side-effect information is a feature, not a liability: it's how you and your provider decide together whether a treatment fits. Where an effect has its own article — nausea, hair shedding, fatigue — you'll find the detail there.
56 articles on this topic
-

Does Semaglutide Make You Tired? What Trials Show
Yes, fatigue can happen, though it was reported by a minority of people in STEP trials. The timing and accompanying symptoms help distinguish low intake or dehydration from hypoglycemia or another cause.
-

Semaglutide and Alcohol: What to Know
There is no listed direct interaction between semaglutide and alcohol, but the combination can make nausea, dehydration, low blood sugar, and pancreatitis risk more important.
-

Does Tirzepatide Make You Tired? What Trials Say
Fatigue was reported by 5–7% of trial participants on tirzepatide against 3% on placebo. The more useful question is what is actually causing it.
-

NAD Injection Side Effects: What Is Reported
Published intravenous data describe transient infusion-associated symptoms in one small retrospective series and no reported adverse events in an earlier slow-infusion pilot; because the studies differed in design and did not randomize infusion rate, they do not establish speed as the cause.
-

TB-500 Side Effects: What Is Known and What Is Not
Most of what circulates as a TB-500 side effect list is neither reported nor ruled out. The honest version starts with how thin the human safety data is — and with why a seller's clean record is not one.
-

Ipamorelin Side Effects: What Human Data Shows
Human safety data for ipamorelin are unusually thin. Short-term reports exist, but no published trial tells us how common side effects are with months or years of compounded use.
-

Tirzepatide Diarrhea: How Long It Lasts
Diarrhea is common with tirzepatide, especially after treatment begins or the dose increases. It is usually temporary, but persistent symptoms can cause dehydration and deserve a clinician's attention.
-

Tirzepatide and Thyroid Cancer: What We Know
The boxed warning comes from thyroid C-cell tumors in rats, not proof of human cancer. Human studies conflict, so MTC and MEN 2 history remains the decisive screening issue.
-

Does Semaglutide Cause Hair Loss?
In the pooled 68-week trials, hair loss was reported by 3% of adults on semaglutide 2.4 mg against 1% on placebo. Telogen effluvium after fast weight loss explains it better than any proven effect on the follicle.
-

MOTS-c Side Effects: What Is Known and What Is Not
No completed human trial has measured them. What gets sold as a MOTS-c side-effect profile is assembled from injection-site experience with subcutaneous peptides, from pharmacology, and from what a prescriber screens for.
-

Are Peptides Safe? What the Risk Depends On
Safety is not a property a molecule carries on its own. It belongs to the compound plus a dose, plus the vial it came from, plus the person injecting it, plus someone qualified who is accountable for the decision.
-

Does Tirzepatide Cause Hair Loss?
In the pivotal 72-week obesity trials, hair loss was reported by about 3%–7% of tirzepatide groups versus about 1% with placebo. Weight-loss-related telogen effluvium is the leading explanation, but a direct drug effect has not been ruled out.
-

BPC-157 Side Effects and the Evidence Gap
[FDA's July 2026 briefing](https://www.fda.gov/media/193343/download) identifies three indexed uncontrolled reports describing BPC-157 exposure in 31 people, plus two older controlled enema studies reported only as meeting abstracts. That limited record, more than any list of symptoms, is the honest answer to what its side effects are.
-

Sermorelin Side Effects, by the Numbers
About one patient in six gets a reaction where the needle went in. Almost everything else on the list occurs in under 1% — but the trial data behind those numbers comes from a population that may not look like you.
-

Tirzepatide Side Effects, From Common to Rare
Gastrointestinal effects are the ones almost everyone asks about — and across the tirzepatide dose range they affect 39% to 49% of people, concentrated in the weeks when the dose is going up.
-

Semaglutide Side Effects, From Common to Rare
Across pooled STEP-trial safety data, only 4.3% of adults taking semaglutide 2.4 mg stopped treatment because of gastrointestinal side effects.
Page 3 of 3 · 56 articles